The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

IO Biotech plans to meet with the FDA this fall to discuss the data from the phase 3 trial of Cylembio and determine next ...

We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Pfizer Inc. (NYSE:PFE) is one of the ...

The combination of Padcev and Keytruda delivered a phase 3 win in muscle-invasive bladder cancer. China did not renew the conditional approval for a controversial Alzheimer's disease drug. | The ...

Schrödinger announced it will discontinue clinical development of the CDC7 inhibitor SGR-2921 for acute myeloid leukemia (AML) and myelodysplastic syndromes following two patient deaths in an ...

The Nobel Prize-winning technology underpinning COVID-19 vaccines is also fueling a host of biotechs developing treatments ...

Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.

We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Merck & Co., Inc. (NYSE:MRK) is one of ...

AstraZeneca expects continued growth of its oncology medicines in the second half, particularly Tagrisso, Enhertu, and ...

MSD wouldn't comment on whether the cost cutting will result in jobs losses at any of its Irish plants including at Ballydine ...

Investment in American manufacturing is on the rise, with pharmaceutical giant Merck recently announcing a landmark $1 billion investment to establish a manufacturing plant in Wilmington, Delaware.